| 14th Jan 2026 7:00 am |
RNS-R |
Publication of Phase III Results in The Lancet |
| 7th Jan 2026 7:00 am |
RNS-R |
Positive Topline Results of Phase III Trial |
| 5th Jan 2026 7:00 am |
RNS-R |
Surufatinib + Camrelizumab PDAC Phase 3 initiation |
| 31st Dec 2025 7:00 am |
RNS |
Total Voting Rights |
| 31st Dec 2025 7:00 am |
RNS |
Total Voting Rights |
| 30th Dec 2025 10:00 am |
RNS-R |
China NDA Acceptance-Savolitinib in Gastric Cancer |
| 30th Dec 2025 10:00 am |
RNS-R |
China NDA Acceptance-Savolitinib in Gastric Cancer |
| 29th Dec 2025 8:30 am |
RNS |
Blocklisting Six Monthly Return |
| 29th Dec 2025 8:30 am |
RNS-R |
NDA Acceptance in China for Fanregratinib |
| 29th Dec 2025 8:30 am |
RNS-R |
NDA Acceptance in China for Fanregratinib |
| 29th Dec 2025 8:30 am |
RNS |
Blocklisting Six Monthly Return |
| 17th Dec 2025 7:00 am |
RNS-R |
HUTCHMED Initiates Development of ATTC Candidate |
| 8th Dec 2025 7:00 am |
RNS |
Expanded NRDL Coverage + CIDL Inclusion in China |
| 28th Nov 2025 8:30 am |
RNS |
Total Voting Rights |
| 27th Nov 2025 7:00 am |
RNS-R |
HUTCHMED Highlights Data at ESMO and ASH |
| 5th Nov 2025 7:00 am |
RNS-R |
Enrollment Complete in SAFFRON Global Phase III |
| 3rd Nov 2025 7:00 am |
RNS-R |
Updates from R&D Event |
| 23rd Oct 2025 7:00 am |
RNS-R |
HUTCHMED Presents Data at AACR NCI EORTC |
| 21st Oct 2025 9:30 am |
RNS |
Vesting of awards under Long Term Incentive Plan |
| 14th Oct 2025 9:30 am |
RNS |
Appointment of Independent Non-executive Director |
| 13th Oct 2025 7:05 am |
RNS-R |
Data to be Presented at the 2025 ESMO Congress |
| 2nd Oct 2025 7:00 am |
RNS-R |
HUTCHMED Highlights Data to be Presented at ESMO |
| 30th Sep 2025 9:30 am |
RNS |
Total Voting Rights |
| 12th Sep 2025 7:00 am |
RNS-R |
HUTCHMED to Present R&D Updates on October 31 2025 |
| 5th Sep 2025 7:00 am |
RNS-R |
HUTCHMED Highlights Data to be Presented at CSCO |
| 26th Aug 2025 7:00 am |
RNS |
Directorate Change |
| 20th Aug 2025 7:00 am |
RNS-R |
HUTCHMED Completes Enrollment of Phase III Trial |
| 7th Aug 2025 12:00 pm |
RNS |
2025 Interim Results |
| 3rd Jul 2025 9:30 am |
RNS |
HUTCHMED to Announce 2025 Half-Year Results |
| 2nd Jul 2025 10:00 am |
RNS |
Update on Joint Corporate Brokers in London |
| 30th Jun 2025 9:30 am |
RNS |
China Approval based on Phase III SACHI Trial |
| 30th Jun 2025 9:30 am |
RNS |
Total Voting Rights |
| 30th Jun 2025 9:30 am |
RNS |
Blocklisting Six Monthly Return |
| 10th Jun 2025 11:00 am |
RNS |
Grant of Share Options and Awards under LTIP |
| 5th Jun 2025 7:00 am |
RNS-R |
HUTCHMED and Innovent Announce NDA Acceptance |
| 2nd Jun 2025 7:00 am |
RNS-R |
HUTCHMED Highlights SACHI Phase III Data at ASCO |
| 30th May 2025 9:30 am |
RNS |
Total Voting Rights |
| 23rd May 2025 7:00 am |
RNS-R |
HUTCHMED Highlights Data to be Presented at ASCO |
| 13th May 2025 11:45 am |
RNS |
AGM held on May 13, 2025 – Poll Results |
| 24th Apr 2025 7:00 am |
RNS-R |
HUTCHMED - Data to be Presented at AACR 2025 |
